Joint pain injections market projected to reach US$9.20B by 2030, with CAGR growth of 8.6% from 2022-2030; growth driven by rise in osteoarthritis and musculoskeletal illnesses, increased patient awareness of this treatment option

Sample article from our Health Care Sector

May 1, 2023 (press release) –

The global joint pain injections market size was USD 4.79 billion in 2022. The market is projected to grow from USD 5.16 billion in 2023 to USD 9.20 billion by 2030, exhibiting a CAGR of 8.6% during the forecast period. Fortune Business Insights™ presents this information in its report titled “Joint Pain Injections Market Size, Share & COVID-19 Impact Analysis, By Product (Corticosteroid Injections, Hyaluronic Acid Injections, Platelet Rich Plasma Injections, and Others), By Joint Type (Knee, Hip, Hand & Wrist, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2023-2030”.

The rise in patients experiencing joint pain and its complications can be attributed to osteoarthritis and musculoskeletal illnesses' rising incidence in the general population. One of the main causes of the rising demand for intra-articular injections for the treatment of joint pain in both developed and developing nations is the patient population's growing awareness of the condition and available treatment choices. The advantageous reimbursement rules in wealthy countries are also to blame for the rising number of therapies. The demand for joint injections is rising in part due to increased knowledge of the advantages of intra-articular injections in the treatment of joint pain.

Market's Development was Limited by Elective Procedures' Deferral under COVID-19

Due to the sharp reduction in product sales, the major market players reported a decline in revenues during the COVID-19 period. Less patient visits for treatment, fewer elective treatments, and the reallocation of healthcare resources for COVID-19 management were all factors in the sharp fall in revenue for the pain injections market. Another element that contributed to the market's decrease was the increased use of alternative therapies during the pandemic, including oral medications and others. Major players consequently predicted a sharp fall in growth in 2020.

DUROLANE Therapies Improved Patients Osteoarthritis

According to updated Clinical Practice Guidelines (CPG) from the American Academy of Orthopedic Surgeons (AAOS), certain knee osteoarthritis (OA) patients improved statistically with the use of high molecular weight cross-linked hyaluronic therapies such as DUROLANE.

Increasing R&D Activity among Big Businesses and Pipeline Candidates to Support Product Demand

The demand for pain injections in the market is anticipated to increase due to the rising prevalence of musculoskeletal illnesses, such as osteoarthritis, and the rising diagnostic rate among the general population. The market acceptance of these items is projected to be boosted by the main players' rising R&D efforts to expand their product portfolios and create unique products in response to the market's growing patient population needs. Another important factor that is anticipated to fuel market development is the increasing number of pipeline candidates by the market's major players.

The market is expected to grow as a result of all the aforementioned factors as well as an increase in partnerships and collaborations between established companies and startups to create and sell cutting-edge treatments and products for a range of musculoskeletal disorders.

However, joint pain injections market growth is expected to be constrained by a number of important factors, including the high cost of these injections and strict regulations for product approvals.

To get a detailed report summary and research scope of this market, click here:

Competitive Landscape

Strong Player Portfolio to Strengthen Market Position

Injections used to treat joint pain are widely used worldwide; however, this industry is fragmented with several companies.

The dominant companies in the market in 2022 included Sanofi, Bioventus Inc., Anika Therapeutics Inc., and others. The powerful distribution network, tactical alliances, and diverse intra-articular injections product portfolio of these players are credited with their supremacy. To acquire a competitive advantage over other market participants, the major corporations active in the space are creating novel products. Furthermore, it is predicted that these companies' growing emphasis on expanding the usability and adoption of their viscosupplementation products will support the join pain injections market share.

Notable Industry Development:

  • July 2022 – Bioventus acquired CartiHeal, an Israel-based company, focused on the development of products for the treatment of osteoarthritis and other musculoskeletal disorders.  

List of Key Players Profiled in the Report

  • Sanofi (France)
  • Bioventus (U.S.)
  • Anika Therapeutics, Inc. (U.S.)
  • Pacira BioSciences, Inc. (U.S.)
  • Reddy’s Laboratories Ltd. (India)
  • Zimmer Biomet (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Ferring B.V. (Switzerland)

Further Report Findings

  • North America led the global joint pain injections market in 2022, contributing to USD 2.15 billion. Increased demand for intra-articular injections in the U.S. and Canada, established reimbursement policies for these procedures, and increasing attention from market players to this demand are the main drivers propelling the expansion of the North America market.
  • The second-largest market share in the global market was held by Europe, where a sizable patient base experiences discomfort from musculoskeletal disorders, including arthritis. Furthermore, growth is anticipated to be stimulated by the availability of qualified experts and the introduction of innovative intra-articular pain injections in the Europe market.
  • This market is anticipated to grow at the fastest rate during the projected period in Asia Pacific. The market expansion in Asian nations is being driven by the rising prevalence of osteoarthritis and the development of viscosupplement products by regional market participants.
  • The global market share of South America, the Middle East, and Africa was lower. Nonetheless, it is anticipated that the market expansion in these regions will be driven by the rising prevalence of arthritis and the increased acceptance of technologically sophisticated pain treatment solutions.

Table of Segmentation



Study Period


Base Year


Estimated Year


Forecast Period


Historical Period


Growth Rate

CAGR of 8.6% from 2023-2030


Value (USD billion)


By Product, Joint Type, Distribution Channel, and Region

By Product

  • Corticosteroid Injections
  • Hyaluronic Acid Injections
  • Platelet Rich Plasma Injections
  • Others

By Joint Type

  • Knee
  • Hip
  • Hand & Wrist
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America (By Product, By Joint Type, By Distribution Channel, By Country)
    • U.S.
    • Canada
  • Europe (By Product, By Joint Type, By Distribution Channel, By Country/Sub-Region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Product, By Joint Type, By Distribution Channel, By Country/Sub-Region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Product, By Joint Type, By Distribution Channel, By Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product, By Joint Type, By Distribution Channel, By Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa




* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Chelsey Quick
Chelsey Quick
- VP Client Success -

We offer built-to-order health care sector coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.